Oculus Innovative SC (OCLS) 4.13 $OCLS
Oculus Innovative Sciences Launches Lasercyn(TM) into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
GlobeNewswire - Tue Aug 30, 3:18AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the commercial launch into the U.S. dermatology market of the company's newest dermatology product, Lasercyn(TM). Under the supervision of a healthcare professional, Lasercyn is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
GlobeNewswire - Wed Aug 24, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new post-dermal-procedures product.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn(R)-Based Antimicrobial Solutions and Hydrogel Dressings
GlobeNewswire - Thu Aug 11, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced that the company's Microcyn(R)-based antimicrobial wound solution and wound hydrogel dressing have received Class IIb medical device registrations from the Australian Government Department of Health as well as Class IIb registrations from the New Zealand Medicines and Medical Devices Safety Authority.
OCLS: 4.13 (+0.04)
Research and Markets - Global Scar Treatment Market 2016-2020 With Avita Medical, CCA Industries, Enaltus, Oculus Innovative Sciences & Pacific World Dominating
PR Newswire Europe - Fri Aug 05, 6:11AM CDT
DUBLIN, August 5, 2016 /PRNewswire/ --
OCLS: 4.13 (+0.04)
SECFilings.com: OCLS Keeping in Step With Innovation and US Dermatology Market Penetration
Marketwire Canada - Thu Aug 04, 8:10AM CDT
REDONDO BEACH, CA--(Marketwired - Aug 4, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces publication of an article examining Oculus Innovative Sciences' (NASDAQ: OCLS) steadily improving performance in the U.S. dermatology market and what that means for the company moving forward.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017
GlobeNewswire - Thu Jul 28, 3:05PM CDT
-- Product Revenue Up 20% Driven by Growth in U.S. Dermatology
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Reverse Split of Common Stock
GlobeNewswire - Wed Jun 22, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced today that a 1-for-5 reverse split of its common stock will be effective after the close of business on Friday, June 24, 2016. The reverse stock split was previously approved by the company's stockholders at the company's special meeting held on June 29, 2015. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-5 on June 2, 2016. The reverse split was not the result of any NASDAQ actions.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Financial Results for the Fiscal Year/Fourth Quarter 2016 and Conference Call
GlobeNewswire - Thu Jun 02, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal year and fourth quarter 2016, ended March 31, 2016, will be released after the U.S. markets close on June 16, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 16, 2016, to discuss fiscal fourth quarter and year end results.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Launches New Ceramax(TM) Skin Barrier Cream in the United States
GlobeNewswire - Tue May 03, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of Ceramax(TM) Skin Barrier Cream, intended to be used as a topical skin care preparation to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at Pioneers 2016 Investor Conference Hosted by Joseph Gunnar & Company in New York City
GlobeNewswire - Thu Apr 28, 4:42AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Robert Miller, the company's CFO/COO, will present a corporate overview and business update at the Pioneers 2016 Investor Conference hosted by Joseph Gunnar & Company. The Oculus presentation is scheduled on Thursday, May 5, 2016, at 2:00 pm EDT at the New York Palace Hotel in New York City.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.85 (-0.02), EBIO: 4.89 (+0.01), OCLS: 4.13 (+0.04)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.38 (-0.04), UNXL: 1.48 (+0.01), ONCS: 1.71 (+0.02), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn(R) Technology
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of several new U.S. and foreign patents relating to its Microcyn Technology hypochlorous acid formulations. Specifically, the company has been granted a U.S. patent, as well as a Canadian patent, for the use of the Oculus Microcyn Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
GlobeNewswire - Wed Mar 30, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid(R) Technology.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
GlobeNewswire - Thu Mar 24, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Sidoti Emerging Growth Conference to be held at the Marriott Marquis in Times Square, New York, NY on Thursday, March 31, 2016. The Oculus presentation is scheduled at 1:00pm EDT.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH(R) Animal Healthcare Products
GlobeNewswire - Wed Mar 23, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced a multi-year licensing agreement with Manna Pro Products, LLC, (www.mannapro.com) for the entire family of MicrocynAH(R) animal healthcare products for the North American large animal and farm/home market.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Launches Lasercyn(TM) into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
GlobeNewswire - Tue Aug 30, 3:18AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the commercial launch into the U.S. dermatology market of the company's newest dermatology product, Lasercyn(TM). Under the supervision of a healthcare professional, Lasercyn is intended for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. Lasercyn may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
GlobeNewswire - Wed Aug 24, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new post-dermal-procedures product.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn(R)-Based Antimicrobial Solutions and Hydrogel Dressings
GlobeNewswire - Thu Aug 11, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced that the company's Microcyn(R)-based antimicrobial wound solution and wound hydrogel dressing have received Class IIb medical device registrations from the Australian Government Department of Health as well as Class IIb registrations from the New Zealand Medicines and Medical Devices Safety Authority.
OCLS: 4.13 (+0.04)
Research and Markets - Global Scar Treatment Market 2016-2020 With Avita Medical, CCA Industries, Enaltus, Oculus Innovative Sciences & Pacific World Dominating
PR Newswire Europe - Fri Aug 05, 6:11AM CDT
DUBLIN, August 5, 2016 /PRNewswire/ --
OCLS: 4.13 (+0.04)
SECFilings.com: OCLS Keeping in Step With Innovation and US Dermatology Market Penetration
Marketwire Canada - Thu Aug 04, 8:10AM CDT
REDONDO BEACH, CA--(Marketwired - Aug 4, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces publication of an article examining Oculus Innovative Sciences' (NASDAQ: OCLS) steadily improving performance in the U.S. dermatology market and what that means for the company moving forward.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017
GlobeNewswire - Thu Jul 28, 3:05PM CDT
-- Product Revenue Up 20% Driven by Growth in U.S. Dermatology
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Reverse Split of Common Stock
GlobeNewswire - Wed Jun 22, 4:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced today that a 1-for-5 reverse split of its common stock will be effective after the close of business on Friday, June 24, 2016. The reverse stock split was previously approved by the company's stockholders at the company's special meeting held on June 29, 2015. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-5 on June 2, 2016. The reverse split was not the result of any NASDAQ actions.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Financial Results for the Fiscal Year/Fourth Quarter 2016 and Conference Call
GlobeNewswire - Thu Jun 02, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal year and fourth quarter 2016, ended March 31, 2016, will be released after the U.S. markets close on June 16, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 16, 2016, to discuss fiscal fourth quarter and year end results.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Launches New Ceramax(TM) Skin Barrier Cream in the United States
GlobeNewswire - Tue May 03, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of Ceramax(TM) Skin Barrier Cream, intended to be used as a topical skin care preparation to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at Pioneers 2016 Investor Conference Hosted by Joseph Gunnar & Company in New York City
GlobeNewswire - Thu Apr 28, 4:42AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Robert Miller, the company's CFO/COO, will present a corporate overview and business update at the Pioneers 2016 Investor Conference hosted by Joseph Gunnar & Company. The Oculus presentation is scheduled on Thursday, May 5, 2016, at 2:00 pm EDT at the New York Palace Hotel in New York City.
OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.85 (-0.02), EBIO: 4.89 (+0.01), OCLS: 4.13 (+0.04)
4 Promising Small Cap Stocks That You Need To Know About
ACCESSWIRE - Wed Apr 20, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 20, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. OCLS, ONCS, CARA and UNXL are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CARA: 5.38 (-0.04), UNXL: 1.48 (+0.01), ONCS: 1.71 (+0.02), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn(R) Technology
GlobeNewswire - Wed Apr 06, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of several new U.S. and foreign patents relating to its Microcyn Technology hypochlorous acid formulations. Specifically, the company has been granted a U.S. patent, as well as a Canadian patent, for the use of the Oculus Microcyn Technology in the treatment of atopic dermatitis. In addition, two new patents in Mexico and Canada have recently been issued to Oculus relating to other hydrogel formulations and antimicrobial solutions.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
GlobeNewswire - Wed Mar 30, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has finalized a strategic collaborative agreement with the Lipogrid Company of Sweden to develop multiple topical drug delivery formulations based upon the company's Lipogrid(R) Technology.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
GlobeNewswire - Thu Mar 24, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Sidoti Emerging Growth Conference to be held at the Marriott Marquis in Times Square, New York, NY on Thursday, March 31, 2016. The Oculus presentation is scheduled at 1:00pm EDT.
OCLSW: 0.23 (-0.01), OCLS: 4.13 (+0.04)
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH(R) Animal Healthcare Products
GlobeNewswire - Wed Mar 23, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced a multi-year licensing agreement with Manna Pro Products, LLC, (www.mannapro.com) for the entire family of MicrocynAH(R) animal healthcare products for the North American large animal and farm/home market.
OCLS: 4.13 (+0.04)
